AI will change the interaction between doctors and patients. But most patients won't even know it's there. That's because improving the patient experience, provider productivity, diagnostic accuracy and overall quality of care won't happen overnight or as part of some massive disruption. The best artificial intelligence (AI) will evolve invisibly with and into the existing care continuum – embedded into workflows, applications and devices already in use today. Today, hospitals store hundreds of millions of digital images, their numbers growing as imaging scanners such as MRIs and CTs become better at capturing thinner and thinner slices of the body – and 3D and 4D images become the norm.
Dave Ryan leads the Global Health & Life Sciences business unit at Intel that focuses on digital transformation from edge-to-cloud in order to make precision, value-based care a reality. His customers are the manufacturers who build life sciences instruments, medical equipment, clinical systems, compute appliances and devices used by research centers, hospitals, clinics, residential care settings and the home. Dave has served on the boards of Consumer Technology Association Health & Fitness Division, HIMSS' Personal Connected Health Alliance, the Global Coalition on Aging and the Alliance for Connected Care. What is Intel's Health & Life Sciences Business? Intel's Health & Life Sciences business helps customers create solutions in the areas of medical imaging, clinical systems, and lab and life sciences, enabling distributed, intelligent, and personalized care.
Disclaimer: This content was commissioned and funded by Bayer AG. The healthcare industry is undergoing a major overhaul in terms of technology, and artificial intelligence (AI) in particular has huge potential to enhance all areas of patient care, from research and development of new therapy options through to diagnosis and treatment of individual patients. The breakthrough in AI is the result of advances in data collection and aggregation, processing power, and deep learning algorithms. Some of the most promising AI applications in healthcare have been in image processing and image analysis, which encompasses the remit of radiology. The medical imaging field has long been a frontrunner of digital innovation in healthcare and now also in the application of AI.
The vast majority of today's healthcare data comes from medical scans, and doctors have become stressed and overburdened as they struggle to interpret the images while managing patient care. By using AI and deep-learning technology to analyze patient scans, doctors can obtain results much faster while also improving diagnostic accuracy. Scans are not as easy to decipher as they may appear. Many contain dozens of images that doctors must pore over to arrive at a diagnosis. Pinpointing the exact location and dimensions of fractures, nodules, and other lesions is often difficult.
This morning AI-enabled handheld ultrasound startup Exo landed $35 million in Series B funding. The new infusion of cash was led by Intel Capital with participation from Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony Innovation Fund and Wanxiang Healthcare Investments. The Redwood City, California-based startup is developing a portable ultrasound that is able to create a 3D image. The company is combining nano-materials, sensor technology and advanced signal processing and computation to create the technology. The new money will be put towards developing the product and helping the startup go through regulatory channels.